The most clinically meaningful difference is half-life and metabolite profile. Lorazepam (Ativan) has a half-life of roughly 10–20 hours and produces no pharmacologically active metabolites — it is broken down directly to an inactive glucuronide and cleared. This makes it predictable in the elderly and in people with liver disease. Alprazolam (Xanax) has a variable half-life of 6–27 hours and its metabolites have some activity of their own. Xanax is also available in an extended-release formulation, and has a specific FDA approval for panic disorder. Both are Schedule IV controlled substances. Neither drug is universally safer or stronger — the right choice depends on the clinical indication, the patient's age, liver function, and the risk profile your prescriber is managing.

Ativan (lorazepam) undergoes a relatively simple phase II conjugation reaction (glucuronidation) that is largely preserved even in compromised liver function, unlike the phase I oxidative metabolism that breaks down alprazolam into weakly active metabolites. Because lorazepam produces no active metabolites, there is no downstream accumulation — the duration of effect is set by the drug itself, not by unpredictable metabolite clearance. This makes lorazepam's effects more predictable in populations where drug handling is altered. That said, the safest approach is generally to avoid benzodiazepines in older adults whenever possible; when one cannot be avoided, guidelines tend to favor the "LOT" agents — Lorazepam, Oxazepam, Temazepam — over longer-acting or oxidatively metabolized alternatives.

Both are Schedule IV controlled substances and both carry FDA boxed warnings for dependence. That said, alprazolam (Xanax) is more associated with recreational abuse and misuse. The reason is pharmacokinetic: alprazolam has a faster onset and a sharper peak in blood levels, producing a more pronounced euphoric effect that reinforces drug-seeking behavior. Lorazepam's onset is more gradual. Additionally, the rapid offset of immediate-release Xanax produces more noticeable interdose rebound and withdrawal, which can drive compulsive redosing. Extended-release alprazolam blunts the peak but does not eliminate this pattern. Neither drug should be used recreationally, and both require prescriber-supervised tapering when stopping after regular use.

There is overlap in indications but also important differences. Both are used for generalized anxiety disorder and situational anxiety. Alprazolam has a specific FDA approval for panic disorder (including with agoraphobia) — lorazepam does not. Lorazepam has approvals alprazolam lacks: status epilepticus (IV), preoperative sedation, and alcohol withdrawal management. In practice, the prescriber matches the drug to the indication, the available route of administration, and the patient's medical profile.

Switching between benzodiazepines is a clinical decision that should never happen without prescriber guidance. While dose-equivalence tables exist, individual responses vary significantly, and a poorly managed switch can precipitate withdrawal symptoms or unexpected over-sedation. In practice, clinicians sometimes switch patients from short-acting alprazolam to a longer-acting agent as part of a structured taper strategy — the extended half-life allows blood levels to decline more gradually when the taper begins. Whether this is appropriate for you depends on your history, current regimen, and treatment goals. Never adjust or stop either medication without explicit guidance from your prescriber.

Xanax XR (extended-release alprazolam) is designed to release the medication more slowly over the day, smoothing out the sharp peaks and troughs that characterize immediate-release alprazolam. This reduces the intensity of interdose rebound anxiety — the heightened anxiety some patients feel as a dose wears off before the next is due — and is specifically indicated for panic disorder. Lorazepam has no extended-release form. Its intermediate half-life provides some natural smoothing compared to very short-acting agents, but it cannot achieve the same sustained blood-level profile that Xanax XR provides. Whether XR is appropriate for a given patient depends on their diagnosis and history, as the XR form still carries dependence risks.